OmniAb (NASDAQ:OABI) Posts Earnings Results, Beats Estimates By $0.07 EPS

OmniAb (NASDAQ:OABI) posted its earnings results on Thursday. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.07, FiscalAI reports. OmniAb had a negative net margin of 115.12% and a negative return on equity of 16.45%. The business had revenue of $13.41 million for the quarter, compared to analyst estimates of $4.69 million.

Here are the key takeaways from OmniAb’s conference call:

• Q2 revenue rose to $13.4 million from $3.9 million year over year, driven primarily by partner milestone revenue; net loss narrowed to $5.9 million from $15.9 million.
• OmniAb raised and narrowed its 2026 guidance, now forecasting revenue of $32 million–$36 million, GAAP operating expenses of $84 million–$88 million, and year-end cash of $37 million–$41 million.
• The partnered pipeline continued to advance, with 425 active programs, 34 active clinical programs or approved products, four new clinical entrants in 2026, and approximately $340 million in remaining potential milestones tied to clinical-stage programs.
• The company sold two xPloration instruments during Q2, bringing the field total to four, and said the platform could generate recurring revenue from consumables, software, maintenance, and services.
• Revenue remains heavily dependent on milestone timing and was front-loaded in the first half of 2026; despite improved cash use, OmniAb expects to end the year with less cash than the $52 million held at the end of Q2.

OmniAb Price Performance

OmniAb stock traded up $0.84 during midday trading on Friday, hitting $3.08. 2,672,840 shares of the company were exchanged, compared to its average volume of 402,782. The company has a market cap of $445.92 million, a PE ratio of -8.56 and a beta of 0.45. OmniAb has a fifty-two week low of $1.30 and a fifty-two week high of $3.12. The company’s fifty day moving average price is $2.26 and its 200-day moving average price is $1.96.

Institutional Trading of OmniAb

A number of hedge funds have recently made changes to their positions in OABI. AQR Capital Management LLC purchased a new position in shares of OmniAb in the first quarter valued at $25,000. Osaic Holdings Inc. lifted its holdings in OmniAb by 214.4% in the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after buying an additional 9,716 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in OmniAb by 92.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock worth $35,000 after buying an additional 10,438 shares in the last quarter. Cerity Partners LLC boosted its position in OmniAb by 111.5% in the 2nd quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock valued at $39,000 after buying an additional 11,919 shares during the last quarter. Finally, Corient Private Wealth LLC purchased a new position in OmniAb in the 2nd quarter valued at about $53,000. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded OmniAb from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.